Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens

Cancer Research

Volumn 70, Issue 4, 2010, Pages 1344-1355

  Marina, Ovidiu ^a,d   Hainz, Ursula ^a   Biernacki, Melinda A ^a,e   Zhang, Wandi ^a   Cai, Ann ^b   Duke Cohan, Jonathan S ^a,b   Liu, Fenglong ^a   Brusic, Vladimir ^a   Neuberg, Donna ^a   Kutok, Jeffery L ^b,c   Alyea, Edwin P ^a,b,c   Canning, Christine M ^a   Soiffer, Robert J ^a,b,c   Ritz, Jerome ^a,b,c   Wu, Catherine J ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

^e UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; B LYMPHOCYTE ANTIGEN; C6ORF130 ANTIGEN; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DAPK3 ANTIGEN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GENOMIC DNA; MDS032 ANTIGEN; MELPHALAN; MINOR HISTOCOMPATIBILITY ANTIGEN; MYELOABLATIVE AGENT; OGFOD1 ANTIGEN; PREDNISONE; SERBP1 ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; VINCRISTINE; ZFYVE19 ANTIGEN;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; BONE MARROW TRANSPLANTATION; CANCER CELL; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DETERIORATION; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOGENICITY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SEROLOGY; T CELL DEPLETION; TUMOR IMMUNITY;

ANTIGENS, SURFACE; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CELL LINEAGE; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNODOMINANT EPITOPES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 76749123948     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3143     Document Type: Article

References (48)

1. Byrd JC, Lin TS, Grever MR. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies. Semin Oncol 2006;33: 210-9.
2. Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 2001;15:445-51.
3. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007;21:12-7.
4. Pavletic SZ, Khouri IF, Haagenson M, et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol 2005;23: 5788-94.
5. Rondon G, Giralt S, Huh Y, et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996;18:669-72.
6. Toze CL, Galal A, Barnett MJ, et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant 2005;36:825-30.
7. Collins RH, Jr., Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-44.
8. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006;107:1724-30.
9. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graftversus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003;21:2747-53.
10. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005;106:4389-96.
11. Wu CJ, Ritz J. The induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol 2006;90:129-69.
12. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005;105:2973-8.
13. Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000;106:705-14.
14. Bellucci R, Alyea EP, Chiaretti S, et al. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood 2005; 105:3945-50.
15. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-70.
16. Trojan A, Schultze JL, Witzens M, et al. Immunoglobulin frameworkderived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000;6:667-72.
17. Krackhardt AM, Witzens M, Harig S, et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002;100:2123-31.
18. + autologous T lymphocytes. Exp Hematol 2006;34:44-53.
19. Giannopoulos K, Schmitt M. Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:2028-36.
20. Marina O, Biernacki MA, Brusic V, Wu CJ. A concentration-dependent analysis method for high density protein microarrays. J Proteome Res 2008;7:2059-68.
21. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-38.
22. Tsai J, Sultana R, Lee Y, et al. RESOURCERER: a database for annotating and linking microarray resources within and across species. Genome Biol 2001;2:SOFTWARE0002.
23. Zuo D, Mohr SE, Hu Y, et al. PlasmID: a centralized repository for plasmid clone information and distribution. Nucleic Acids Res 2007;35:D680-4.
24. Rual JF, Hirozane-Kishikawa T, Hao T, et al. Human ORFeome version 1.1: a platform for reverse proteomics. Genome Res 2004;14: 2128-35.
25. Lennon G, Auffray C, Polymeropoulos M, Soares MB. The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression. Genomics 1996;33:151-2.
26. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998;91:3671-80.
27. Wheeler DL, Barrett T, Benson DA, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2007;35:D5-12.
28. Liebel U, Kindler B, Pepperkok R. 'Harvester': a fast meta search engine of human protein resources. Bioinformatics 2004;20:1962-3.
29. Gurkan C, Lapp H, Hogenesch JB, Balch WE. Exploring trafficking GTPase function by mRNA expression profiling: use of the SymAtlas web-application and the Membrome datasets. Methods Enzymol 2005;403:1-10.
30. Haslinger C, Schweifer N, Stilgenbauer S, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004;22:3937-49.
31. Ramos TC, Vinageras EN, Ferrer MC, et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a phase I trial. Cancer Biol Ther 2006;5:145-9.
32. Biernacki MA, Zhang GL, Zhang W, et al. Novel myeloma-associated antigens revealed in the context of successful syngeneic hematopoietic stem cell transplantation. American Society of Hematology 50th Annual Meeting; Dec 6-11, 2008, San Francisco (CA). 2008.
33. Regnault A, Lankar D, Lacabanne V, et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999;189:371-80.
34. Valmori D, Souleimanian NE, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 2007;104:8947-52.
35. Brusic V, Marina O, Wu CJ, Reinherz EL. Proteome informatics for cancer research: from molecules to clinic. Proteomics 2007; 7:976-91.
36. Zhu H, Bilgin M, Bangham R, et al. Global analysis of protein activities using proteome chips. Science 2001;293:2101-5.
37. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007; 109:1355-62.
38. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997;16:313-39.
39. + T lymphocytes. Science 2008;319:215-20.
40. Nishida T, Hudecek M, Kostic A, et al. Development of tumorreactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res 2009;15:4759-68.
41. Wierda WG, Kipps TJ. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol 2007;20: 557-68.
42. Gitelson E, Hammond C, Mena J, et al. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res 2003;9:1656-65.
43. Dilcher M, Veith B, Chidambaram S, Hartmann E, Schmitt HD, Fischer von Mollard G. Use1p is a yeast SNARE protein required for retrograde traffic to the ER. EMBO J 2003;22:3664-74.
44. Chinwalla V, Chien A, Odero M, Neilly MB, Zeleznik-Le NJ, Rowley JD. A t(11;15) fuses MLL to two different genes, AF15q14 and a novel gene MPFYVE on chromosome 15. Oncogene 2003;22: 1400-10.
45. Kawai T, Matsumoto M, Takeda K, Sanjo H, Akira S. ZIP kinase, a novel serine/threonine kinase which mediates apoptosis. Mol Cell Biol 1998;18:1642-51.
46. Yu H, Jiang D, Guo Z, et al. TCP10L is expressed specifically in spermatogenic cells and binds to death associated protein kinase-3. Int J Androl 2005;28:163-70.
47. Koensgen D, Mustea A, Klaman I, et al. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. Gynecol Oncol 2007;107: 266-73.
48. Jia Z, Barbier L, Stuart H, et al. Tumor cell pseudopodial protrusions. Localized signaling domains coordinating cytoskeleton remodeling, cell adhesion, glycolysis, RNA translocation, and protein translation. J Biol Chem 2005;280:30564-73.